Unlock regulatory insights with Watson. Learn More

Methodological Considerations in Evaluation of Cancer as an Adverse Outcome Associated With Use of Non-Oncological Drugs and Biological Products in the Postapproval Setting; Public Meeting, Request for Comments

Center CDER
VIEW ALL (3)Primary Documents